MedTrace Logo

The Effect of Long-acting Antipsychotics on Schizophrenia Patients With Violence Risk

NCT04064476 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 225

Last updated 2020-02-20

No results posted yet for this study

Summary

This is a 49 weeks prospective, non-interventional cohort study. To observe the effect of long-acting injection antipsychotic(LAI), paliperidone palmitate on prevention of recurrence and symptom control in schizophrenia patients with violence risk. This study can be extended according to the implementation of the project and extended follow-up time.

Conditions

Interventions

DRUG

Paliperidone Palmitate

This is a observational study, to see the effect of paliperidone palmitate on schizophrenia patient with violence risk. The intervention is determined by clinical practice in real world setting, only schizophrenia patient with violence risk and treated with Paliperidone Palmitate will be invited to join the observational study.

Sponsors & Collaborators

  • Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Yi Li, Dorctor · HuaZhong university, Wuhan mental health center

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-18
Primary Completion
2021-08-15
Completion
2021-09-15
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04064476 on ClinicalTrials.gov